Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Gadoversetamide' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadoversetamide' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
Searchterm 'Gadoversetamide' was also found in the following service: 
spacer
News  (1)  
 
GadoversetamideInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-DTPA-BMEA, generic name: Gadoversetamide
A paramagnetic extracellular MRI contrast agent with positive enhancement. When placed in a magnetic field, gadoversetamide decreases T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity (brightness).

See Contrast Agents and OptiMARK™.
spacer
 
• Share the entry 'Gadoversetamide':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Gadoversetamide' (1).Open this link in a new window.
 
Further Reading:
  Basics:
OptiMARK® (gadoversetamide injection)
  News & More:
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Equipment - Case Studies - Jobs - - Colonography - Breast Implant
 
OptiMARK®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
OptiMARK® is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide (gadoversetamide), for use as a paramagnetic MRI contrast agent. OptiMARK® (gadoversetamide injection) is to be administered by intravenous injection. OptiMARK® is indicated for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoversetamide, Gd-DTPA-BMEA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Paramagnetic
PHARMACOKINETIC
Intravascular, extracellular
1110 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1 mmol/kg / 0.2 mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale / Phase III
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20, 50 mL and Pre-filled syringes of 10, 15, 20 and 30 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
OptiMARK®
for sale
Australia
OptiMARK®
for sale
spacer

• View the DATABASE results for 'OptiMARK®' (5).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
OptiMARK® , package insert
MATERIAL SAFETY DATA SHEET
OptiMARK® (gadoversetamide injection)
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
MRI Resources 
Implant and Prosthesis pool - MR Myelography - Process Analysis - Shielding - Patient Information - Colonography
 
Nonionic Intravenous Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Radiographic low-osmolar nonionic contrast agents have less side effects and fewer nephrotoxicity than ionic, high-osmolar agents. Gadolinium-based MRI contrast agents have a different formulation from iodinated X-ray contrast media, and there is no known cross sensitivity between these two types of contrast agents. Intravenous MRI contrast agents, specifically the gadolinium chelates have a high safety and lack of nephrotoxicity compared with X-ray contrast media.
The used gadolinium chelates differ in following properties: linear (e.g., gadodiamide and gadoversetamide have nonionic linear structures) vs. macrocyclic cores, and ionic vs. nonionic types. The nonionic molecules have lower osmolality and viscosity, which increase digestibility at greater concentrations, and make faster bolus injections conceivable. The macrocyclic molecules (e.g., gadoteridol has a nonionic macrocyclic ring structure) are more stable and show fewer tendencies to dissociate free Gd.

See also ProHance®, Omniscan®, OptiMARK®, Ionic Intravenous Contrast Agents.

See also the related poll result: 'MRI will have replaced 50% of x-ray exams by'
spacer

• View the DATABASE results for 'Nonionic Intravenous Contrast Agents' (4).Open this link in a new window

 
Further Reading:
  News & More:
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
   by arpa.allenpress.com    
Searchterm 'Gadoversetamide' was also found in the following service: 
spacer
News  (1)  
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 23 April 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]